Therapeutic niche of hyaluronic acid derivatives in osteoarthritis
| Autor: | I. G. Krasivina, L. N. Dolgova, N. V. Dolgov |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2021 |
| Předmět: |
Drug
local injection media_common.quotation_subject elastic modulus Osteoarthritis Drug molecule Bioinformatics chemistry.chemical_compound synovial fluid Hyaluronic acid hyaluronic acid medicine Synovial fluid In patient media_common Viscoelastic Substances business.industry General Medicine viscosity modulus medicine.disease Controlled release osteoarthritis chemistry crossing frequency Medicine business |
| Zdroj: | Медицинский совет, Vol 0, Iss 10, Pp 123-132 (2021) |
| ISSN: | 2658-5790 |
| Popis: | Osteoarthritis (OA) is a widespread disease of synovial joints, the treatment of which determines a significant number of tactical and strategic directions. Currently, there is experience in the local use of so-called synovial fluid (SF) prostheses, which are viscoelastic substances that improve the cushioning properties of the native intra-articular environment. The overwhelming majority of viscoelastic additives are represented by hyaluronic acid (HA) derivatives, a natural component of SF, whose biological role consists in maintaining the rheological properties of fluid and the presence of anti-inflammatory, anti-nociceptive and chondro-protective properties. In the development of HA drugs, the main goals are the sustained and controlled release of therapeutic doses of the drug, taking into account the choice of carrier, drug molecule and target articular tissue. Assessing the quality and physiological feasibility of introducing a particular viscoelastic drug into the joint involves determining the so-called crossover frequency - the point of intersection of the viscosity modulus G’ and the elastic modulus G” (G’/G”), which reflects changes in the viscoelastic properties of the SF with increasing load frequency when transitioning from walking to running. Physiological range of frequencies out of the majority of investigated medical products corresponds to a single one, among which there are also variants of domestic production. Numerous studies of local application of some HA drugs in patients with OA confirm their effectiveness and safety, in particular, reduction of pain syndrome, reduction of the need for nonsteroidal anti-inflammatory drugs, improvement of the quality of life. However, unfortunately, most HA drugs available on the market have not undergone full-fledged clinical trials, so there is a need to study the comparative effectiveness of drugs of this group approved for use and determine their place in the treatment of OA with different variants of the course. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|